Patents by Inventor Antonia Periclou

Antonia Periclou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220340650
    Abstract: Disclosed are methods for treating headache, migraine and related symptoms by administering a long acting calcitonin gene related peptide (CGRP) antagonist and a short acting CGRP antagonist. Specifically, the disclosure provides a method for treating, preventing, alleviating, or reducing the frequency of occurrence of headache in a patient in need thereof, comprising administering to the patient: (a) a first calcitonin gene related peptide antagonist (CGRP antagonist) and (b) a second CGRP-antagonist, wherein the first CGRP antagonist is an antibody, and the second CGRP antagonist has a plasma half-life in humans of at most about 60 hours.
    Type: Application
    Filed: September 25, 2020
    Publication date: October 27, 2022
    Inventors: Abhijeet Jakate, Antonia Periclou, Ramesh Boinpally
  • Publication number: 20200268685
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: April 17, 2020
    Publication date: August 27, 2020
    Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
  • Patent number: 10660868
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: May 26, 2020
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Suneel K Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G Dedhiya, Shashank Mahashabde
  • Publication number: 20160346227
    Abstract: The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.
    Type: Application
    Filed: August 11, 2016
    Publication date: December 1, 2016
    Inventors: Mahendria G. Dedhiya, Suneel K. Rastogi, Anil Chhettry, Narasimhan Mani, Niranjan Rao, Antonia Periclou
  • Publication number: 20160324803
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: July 20, 2016
    Publication date: November 10, 2016
    Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
  • Publication number: 20150258042
    Abstract: The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.
    Type: Application
    Filed: May 27, 2015
    Publication date: September 17, 2015
    Inventors: Mahendra G. DEDHIYA, Suneel K. RASTOGI, Anil CHHETTRY, Narasimhan MANI, Niranjan RAO, Antonia PERICLOU
  • Publication number: 20150258031
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: May 27, 2015
    Publication date: September 17, 2015
    Inventors: Suneel K. RASTOGI, Niranjan RAO, Antonia PERICLOU, Wattanaporn ABRAMOWITZ, Mahendra G. DEDHIYA, Shashank MAHASHABDE
  • Publication number: 20150148427
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 28, 2015
    Inventors: Suneel K. RASTOGI, Niranjan RAO, Antonia PERICLOU, Wattanaporn ABRAMOWITZ, Mahendra G. DEDHIYA, Shashank MAHASHABDE
  • Publication number: 20140348932
    Abstract: The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.
    Type: Application
    Filed: August 6, 2014
    Publication date: November 27, 2014
    Inventors: Yan YANG, Rajiv JANJIKHEL, Niranjan RAO, Antonia PERICLOU, Wattanaporn ABRAMOWITZ, Mahendra G. DEDHIYA, Erhard SEILLER, Bernhard HAUPTMEIER
  • Patent number: 8834924
    Abstract: The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: September 16, 2014
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Yan Yang, Rajiv Janjikhel, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Erhard Seiller, Bernhard Hauptmeier
  • Publication number: 20140213659
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 31, 2014
    Applicant: Forest Laboratories Holdings Ltd.
    Inventors: Suneel K. RASTOGI, Niranjan RAO, Antonia PERICLOU, Wattanaporn ABRAMOWITZ, Mahendra G. DEDHIYA, Shashank MAHASHABDE
  • Publication number: 20130310460
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: July 23, 2013
    Publication date: November 21, 2013
    Applicant: Forest Laboratories Holdings Ltd.
    Inventors: Suneel K. RASTOGI, Niranjan RAO, Antonia PERICLOU, Wattanaporn ABRAMOWITZ, Mahendra G. DEDHIYA, Shashank MAHASHABDE
  • Publication number: 20130302430
    Abstract: The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.
    Type: Application
    Filed: July 17, 2013
    Publication date: November 14, 2013
    Inventors: Mahendra G. DEDHIYA, Suneel K. RASTOGI, Anil CHHETTRY, Narasimhan MANI, Niranjan RAO, Antonia PERICLOU
  • Publication number: 20130011474
    Abstract: The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: FOREST LABORATORIES HOLDINGS LTD.
    Inventors: Mahendra G. DEDHIYA, Suneel K. RASTOGI, Anil CHHETTRY, Narasimhan MANI, Antonia PERICLOU, Niranjan Rao
  • Publication number: 20130012593
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions, following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: Forest Laboratories Holdings Ltd.
    Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
  • Publication number: 20120201889
    Abstract: The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.
    Type: Application
    Filed: February 15, 2012
    Publication date: August 9, 2012
    Applicant: Forest Laboratories Holdings Ltd.
    Inventors: Mahendra G. Dedhiya, Suneel K. Rastogi, Anil Chhettry, Narasimhan Mani, Antonia Periclou, Niranjan Rao
  • Publication number: 20120004318
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: September 15, 2011
    Publication date: January 5, 2012
    Applicant: FOREST LABORATORIES HOLDINGS LTD.
    Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
  • Patent number: 8039009
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Grant
    Filed: June 16, 2005
    Date of Patent: October 18, 2011
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
  • Publication number: 20110236439
    Abstract: The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.
    Type: Application
    Filed: June 8, 2011
    Publication date: September 29, 2011
    Applicant: FOREST LABORATORIES HOLDINGS LIMITED
    Inventors: Yan Yang, Rajiv Janjikhel, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Erhard Seiller, Bernhard Hauptmeier
  • Publication number: 20100028427
    Abstract: The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.
    Type: Application
    Filed: March 24, 2009
    Publication date: February 4, 2010
    Applicant: Forest Laboratories, Inc.
    Inventors: Yan Yang, Rajiv Janjikhel, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Erhard Seiller, Bernhard Hauptmeier